Organization (Academic)
UNIVERSITY OF DUNDEE
ClinicalTrials.gov lists UNIVERSITY OF DUNDEE as lead sponsor of 113 trials. It has 4 active development programs and 74 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers UNIVERSITY OF DUNDEE: 113 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (108)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 23 |
| Asthma | 17 |
| Diabetes Mellitus, Type 2 | 10 |
| Hepatitis C | 9 |
| Pulmonary Disease, Chronic Obstructive | 9 |
Showing 5 of 108 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 3 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 5 |
| 2019 | 10 |
| 2018 | 13 |
| 2017 | 14 |
| 2016 | 18 |
Showing 10 of 23 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (4)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Brensocatib | COVID-19 | Phase 3 | 1 |
| Sotagliflozin | Diabetes Mellitus | Phase 2 | 1 |
| Sotagliflozin | Diabetes Mellitus, Type 1 | Phase 2 | 1 |
| Sotagliflozin | Heart Failure | Phase 2 | 1 |
Approved assets (74)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| FLUTICASONE PROPIONATE | 6 |
| Allopurinol | 5 |
| racemic salbutamol | 2 |
| levosalbutamol | 2 |
| Dapagliflozin | 2 |
Showing 5 of 74 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 41% hit target (n=41) | 29% on time (n=45) |
Journals published in (240)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Diabetes | 34 |
| BMJ open | 18 |
| Lancet (London, England) | 16 |
| Diabetologia | 15 |
| Diabetes care | 14 |
Showing 5 of 240 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 73 | 10 | 2025-12-16 |
Organization relationships (58)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Imperial College London | Co sponsors trial with | 5 |
| University of Leicester | Co sponsors trial with | 3 |
| University of Bristol | Co sponsors trial with | 3 |
| University of Oxford | Co sponsors trial with | 3 |
| KU Leuven | Co sponsors trial with | 3 |
Showing 5 of 58 relationships.
Latest dated events (239)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 239 events.
Biomarker capability evidence (167)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ARID3B | Trial sponsor | Named in trial inclusion criteria |
| ARID3B | Trial sponsor | Named in trial inclusion criteria |
| ARID3B | Trial sponsor | Named in trial inclusion criteria |
| ARID3B | Trial sponsor | Named in trial inclusion criteria |
| ARID3B | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 167 evidence rows.
Biomarkers this organization publishes on (1,149)
Shown in this order: most publications first.
Showing 5 of 1,149 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.